 COA |
MSDS |
 HPLC |
NMR |
| CAS No: | 436133-68-5 |
| Molecular formula(MF) | C15H11ClF3N5O4S |
| Molecular Weight(MW): | 449.79 |
| Alias |
| In vitro | DMSO | 89 mg/mL (197.87 mM) |
|---|---|---|
| Ethanol | 13 mg/mL (28.9 mM) | |
| Water | <1 mg/mL | |
| In vivo |
| Description | Kobe0065 is H-Ras-cRaf1 interaction inhibitor, exhibiting potent activity to competitively inhibit the binding of H-Ras·GTP to c-Raf-1 RBD with a Ki value of 46 ± 13 μM. | |
|---|---|---|
| Targets |
|
|
| In vitro |
Kobe0065-family compounds bind to Ras⋅GTP and exhibit antiproliferative activity toward cancer cells carrying the activated ras oncogenes. The compounds efficiently inhibit the interaction of Ras⋅GTP with their multiple effectors including Raf, PI3K, and RalGDS and a regulator/effector Sos and show rather broad binding specificity toward various Ras family small GTPases, which may account for their higher potency at the cellular level compared with that of the in vitro binding inhibition[1]. |
|
| In vivo | Kobe0065 has antitumor activity. The compound-treated tumors show a prominent increase of apoptotic cells without any significant body weight loss[1]. |